A Randomised, Double-Blind, Placebo-Controlled Trial with Vitamin D3 in MS: Subgroup Analysis of Patients with Baseline Disease Activity Despite Interferon Treatment

Table 3

Clinical outcomes in vitamin D- and placebo-treated active subgroup patients.

	Vitamin D		Placebo		𝑃 value
	Baseline	Month 12	Baseline	Month 12
EDSS mean (SD) change	2.2 (0.9)	1.9 (1.1)	1.9 (1.2)	2.0 (1.5)	0.274
		−0.3 (0.6)		−0.1 (0.7)
ARR, mean (SD)	0.67 (0.38)	0.33 (0.62)	0.83 (0.37)	0.47 (0.74)	NS
TTW10, mean (SD) change (seconds)	12.17 (6.27)	10.36 (2.70)	10.35 (7.39)	12.10 (13.5)	0.820
		−2.32 (4.62)		1.16 (7.65)
T25FW, mean (SD) change (seconds)	7.26 (7.8)	5.27 (1.4)	4.54 (0.94)	5.08 (1.14)	0.860
		−1.85 (8.1)		0.44 (0.92)

EDSS: Expanded Disability Status Scale; ARR: annual relapse rate; TTW10: timed 10-foot tandem walk; T25FW: timed 25-foot walk.